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ABSTRACT
Serotonin’s involvement in many physiological processes including anxiety,
stress, compulsivity, and mood has been speculated for decades. Insufficient
progress in our understanding of serotonin chemistry is due to the lack of
effective

tools

to

selectively

measure

this

neurotransmitter

on

a

neurotransmission-relevant time scale in vivo. An analytical technique for
serotonin measurements, fast-scan cyclic voltammetry (FSCV), was pioneered in
the last decade in anesthetized rodents and is beginning to shed light on the
complexity of serotonergic activity on a sub-second timescale. Complementary,
more recent technological innovations have enabled ambient neurotransmitter
levels to be determined every few seconds using a method called fast-scan
controlled-adsorption voltammetry (FSCAV). Chapter 1 of this thesis is an
introduction to the work. In Chapter 2, the traditional experimental challenges that
have thus far limited serotonin measurements are discussed and FSCV is
highlighted as a technology that overcomes these difficulties. In Chapter 3, a
simplified FSCAV module, which can be easily constructed by non-experts in
electronics, is presented. This component is composed of two light-emitting
diodes (LEDs). Together, this thesis showcases the design and application of
improved electrochemical tools for in vivo analysis of neurotransmitters in the
context of psychiatric disorders.
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CHAPTER 1
INTRODUCTION
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1.1 The Serotonergic System
The neurotransmitter serotonin crucially modulates the activity of many neuronal
pathways and is involved in a plethora of physiological processes controlling
mood, emotion, and social behavior (Mann 1999; Edwards & Kravitz 1997).
Previous studies suggest that deficits in serotonin neurotransmission are a factor
in several psychiatric disorders including depression, anxiety, eating disorders,
and obsessive-compulsive disorder (Muller & Jacobs, 2009; Lucki 1998).
Consequently, selective-serotonin reuptake inhibitors (SSRIs) were developed to
increase extracellular serotonin levels by inhibiting serotonin transporters and
hindering the reuptake of serotonin back into the cell (Fuller, Perry, Molloy, 1974;
Fuller

&

Wong,

1977).

SSRIs

are

the

most

commonly

prescribed

pharmacological treatment for the above-mentioned disorders, however clinical
success is inconsistent. The irregularity in therapeutic relief is yet to be
understood due to the lack of suitable tools to selectively probe this elusive
neurochemical on a neurotransmission-relevant timescale in vivo.
Sampling techniques, such as microdialysis, have provided the bulk of our
current comprehension of serotonin dynamics (Miyazaki K.W., Miyazaki, K., &
Doya, 2011; Fuller 1994), however microdialysis’ temporal resolution and large
probe size has prevented a deeper understanding of the real-time influence of
serotonin on brain circuitry (Jaquins-Gerstl & Michael, 2015). In 2009, Hashemi
et al. pioneered rapid (10 ms) measurements of in vivo stimulated serotonin
release and reuptake using fast-scan cyclic voltammetry (FSCV) in the rat
substantia nigra pars reticula (SNR). Using FSCV technology, our lab has just
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begun to shed light on in vivo serotonin dynamics and the role serotonin plays in
psychiatric disorders.

1.2 The Scope of the Thesis
In this thesis, I first describe the traditional challenges of measuring serotonin in
vivo and introduce FSCV as an electroanalytical technique that can overcome
these difficulties. Next, fast-scan controlled-adsorption voltammetry (FSCAV) is
underlined as a cutting-edge technology that allows for the rapid measurement of
ambient neurotransmitter concentrations (Chapter 2). Finally, the development
and characterization of a simplified component for FSCAV instrumentation is
reported (Chapter 3). The outline of this thesis is described below:
Chapter 1: Introduction
Chapter 2: This chapter focuses on the historical difficulties of selectively
targeting the serotonergic system for measurement. Next, FSCV is highlighted as
an emerging method to allow for sub-second detection of phasic serotonin
release and reuptake in particular brain regions of rodents. Furthermore, the
most recent technological advancement for the measurement of ambient
neurotransmitter concentrations using FSCAV are discussed.
Chapter 3: In this chapter, we develop and characterize a simplified component
termed the LED circuit for FSCAV measurements. The LED circuit was designed
to be able to be constructed by a novice in electronics, enabling ambient
neurotransmitter measurements to be performed by a larger community. In vitro
and in vivo analyses were performed and found to be in good agreement
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between the novel LED circuit and the original switch utilized in previous FSCAV
reports.
Chapter 4: The final chapter summarizes the conclusions of this work and
considers the future directions of this research.
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CHAPTER 2
REAL-TIME RESOLUTION MEASUREMENT OF SEROTONIN IN
RODENTS1

1

Robke, R., Parthasarathy, A., Willuhn, I., & Hashemi, P. To be submitted to the
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Investigations of the serotonin system started upon discovery of this messenger
in the 1950s. These studies unearthed critical roles for serotonin both in the brain
and in the body’s periphery. However, much remains to be determined about the
precise functions of serotonin, in particular serotonin neurotransmission in the
brain. Serotonin is thought to be involved in the neurochemical coding of
numerous physiological processes underlying aggression, anxiety, appetite,
impulsivity and compulsivity, mood, social behavior, and stress (Muller & Jacobs,
2009). Serotonin’s involvement in these disorders and others has been assumed
for decades; the cause of the ongoing speculation and insufficient progress in our
understanding, however, is primarily the lack of effective tools to selectively
probe this elusive neurotransmitter on a neurotransmission-relevant time scale in
vivo. Sampling techniques, such as microdialysis, have enriched our current
comprehension of serotonin dynamics significantly (Miyazaki K.W. et al., 2011;
Fuller 1994). However, in general, microdialysis sampling methods lack the
temporal resolution to effectively clarify serotonin function in vivo (Nandi & Lunte,
2009). Serotonin-relevant behaviors depend on environmental cues and specific
actions, therefore high temporal resolution is necessary to unravel the precision
function of serotonin in behavior (Anastasio et al., 2013; Burmeister, Lungren,
Kirschner, & Neisewander, 2004). Additionally, there are ongoing discussions
about the integrity of the chemical data obtained given the high magnitude of
brain tissue damage caused by large sampling probes (Borland, Shi, Yang, &
Michael, 2005; Jaquins-Gerstl & Michael, 2015). In contrast, a more niche
analytical method, fast-scan cyclic voltammetry (FSCV), allows scientists to
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identify and quantify rapid neurotransmission (sometimes referred to as “phasic”)
on a sub-second time scale using microelectrodes that cause minimal tissue
damage (Phillips, Robinson, Stuber, Carelli, & Wightman, 2003; Clark et al.,
2010).
FSCV has been extensively used to study dopamine neurotransmission
on an advanced behavioral platform, primarily elucidating dopamine’s roles in
learning and motivation (e.g., Hamid et al., 2016; Day, Roitman, Wightman, &
Carelli, 2007; Willuhn, Burgeno, Groblewski, Phillips, 2014). More recently,
serotonin FSCV was pioneered in anesthetized rodents and is just beginning to
shed light on the complexity and impact of serotonergic activity (Hashemi,
Dankoski, Petrovic, Keithley, & Wightman, 2009). Complementary, an even more
recent cutting-edge technological evolution enables the measurement of ambient
(sometimes referred to as “tonic”) extracellular neurotransmitter concentration
with FSCV technology using a method called fast-scan controlled-adsorption
voltammetry (FSCAV) (Atcherley, Laude, Parent & Heien, 2013). Importantly,
FSCV and FSCAV can be combined at a single sensor to measure both “phasic”
and “tonic” serotonin concentrations in vivo.
In this chapter, the traditional experimental challenges of measuring
phasic serotonin will be outlined and FSCV will be highlighted as a method that
can overcome these difficulties. The status quo of applying FSCV for
understanding serotonin function in vivo will be highlighted and the existing gaps
in our knowledge will be identified. Suggestions for filling these gaps will be
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offered to better shape the fundamental understanding of serotonin’s roles in the
brain.

2.1 Rapid Measurement of Serotonin In Vivo
It is substantially more difficult to make in vivo measurements of serotonin,
compared to dopamine, a related amine neuromodulator because many
regulatory systems work simultaneously to maintain serotonin homeostasis. The
result of this strict regulation is a relatively low extracellular concentration of this
signaling molecule in comparison to dopamine. The reasons for this strict
homeostasis is multi-tiered, but at the most basic tier, it is likely due to the
immediately toxic effects of high extracellular serotonin levels that can lead to a
fatal disorder termed serotonin syndrome. The profound level of regulation
required to maintain serotonin transmission has thus rendered measurements
challenging and, therefore, this modulator’s involvement in neurological and
psychiatric disorders remained elusive.
In the following section, we will discuss the challenges of measuring
serotonin dynamics in vivo as a function of (1) the contribution of the
concentrated anatomical clustering of serotonin cell bodies in the base of the
mammalian brain, (2) the dynamics of the extracellular presence of the
transmitter, (3) tight regulation at a number of levels, and (4) the detrimental
effects of serotonin’s metabolites on implanted microelectrodes (not problematic
for microdialysis). We speculate that, in the past, these circumstantial factors
have hampered the pace of serotonin research as compared to research
targeting dopamine neurotransmission. Finally, we highlight exciting innovative
8

advancements that have the potential to significantly increase the pace of
serotonin research.

2.1a Neuroanatomy of the Serotonin System
The serotonin network in the central nervous system of mammals originates in
the raphe nuclei, a cluster of brain nuclei with cell groups distributed along the
midline of the midbrain and brainstem (Hornung, 2003). The rostral group of
serotonin neurons in the raphe nuclei project widely to forebrain structures like
the amygdala, the hippocampus and all regions of the neocortex and striatum.
Specifically in the cortex, the fibres innervate the neocortex via the lateral
hypothalamus and the median forebrain bundle (MFB). From the MFB, the fibres
project to the frontal cortex and then traverse posteriorly to innervate parietal,
temporal, and occipital cortices. This widespread innervation of the brain
provides an indication for serotonin’s global function modulating a variety of
fundamentally important processes including sleep and arousal processes,
executive function (mediated by the prefrontal cortex), behavioral control of mood
and emotion, social behavior, impulsivity, compulsivity, and learning and memory
(Muller & Jacobs, 2009). Given this broad presence, in addition to the analytical
challenges described above, it has been difficult to identify more precise roles for
serotonin.
The dorsal raphe nucleus (DRN) is the principal area of cell bodies
containing serotonin that widely innervates the brain. The DRN is embedded in a
central location on the mid-line, directly under the lambda fissure of the rodent
skull. The DRN is located underneath a dense network of core vasculature and
9

the cerebral aqueduct (Paxinos & Watson, 2007). This elusive DRN location
means that targeting serotonin’s main hub is experimentally extremely
challenging due to risk of substantial damage of the surrounding vasculature and
diffusion of infused drugs or viruses into the neighboring aqueduct. It is important
to directly access serotonergic neurons because the detection of phasic
serotonin is still dependent on stimulated release. As of now, there are no known
behaviors that reliably evoke serotonin release. Approaches intended to
overcome this complication have been to target the DRN at an angle instead of
vertically from the top of the skull (Figure 2.1A) (Kirby, Rice, & Valentina, 2000;
Correia et al., 2017), although this strategy introduces many errors, and thus
considerably lowering success rate. Another approach is to target the MFB for
the manipulation of serotonin release, which greatly increases success rate
(Hashemi, Dankoski, Wood, Ambrose, & Wightman, 2011), however, at the cost
of markedly diminished selectivity of target structures by electrical stimulation.

2.1b Heterogeneity and Co-Localization with Other Neurotransmitters in the
DRN
The DRN is neuro-chemically not a homogeneous structure and is innervated by
neurons containing glutamate, GABA, and dopamine (Figure 2.1B) (Charara &
Parent, 1998; Qi et al., 2014; Calizo et al., 2011; Challis et al., 2013; Celada et
al., 2001; Weissbourd et al., 2014). In the DRN and throughout other areas of the
brain, histamine-containing vesicles are often found to be co-localized with
serotonin, and is thought to modulate serotonin transmission via inhibitory H 3
hetero-receptors on serotonin-containing neuron terminals (Chase & Murphy,
10

1973; Russell, Henry, Phebus, & Clemens, 1990; Brown, Stevens, & Haas, 2001;
Haas, Sergeeva, & Selbach, 2008; Threlfell et al. 2004). Due to this high colocalization of numerous neurotransmitters in the DRN, it has been challenging to
selectively target serotonergic neurons and to clarify their role in behavior thus
far.
In order to target serotonin neurons selectively on a genetic platform, and
thereby more selectively stimulate serotonin release for phasic detection, it was
attempted to identify and capitalize on molecular markers to circumvent regional
neuronal heterogeneity. However, previously identified molecular markers that
were considered to be selective for serotonin neurons, ETS domain factor Pet-1
and the serotonin transporter (SERT), have later been shown to be present in
glutamate and other neuronal systems (Liu et al., 2014; Hainer et al., 2015). This
lack of specificity has restricted the development of reliable transgenic rodent cre
lines for optogenetic and chemogenetic targeting of serotonin neurons and
represent yet another reason why our understanding of serotonin’s influence on
neuronal circuits has fallen behind compared to other neurotransmitter systems
in which novel genetic-based techniques are reliably employed (Hersman et al.,
2017; Tye et al., 2013). Currently, tryptophan hydroxylase 2 (TPH2), the enzyme
which catalyzes the first rate-limiting step of serotonin synthesis in the central
nervous system, has the potential to become the first valid platform for selective
genetic modification of the serotonin system due to its exclusive presence in
serotonergic producing cells (Zill et al., 2007; Sakowski et al., 2006; Walther &
Bader, 2003).
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2.1c The Complexity of Serotonin Neurotransmission
The coordinated effort by many, simultaneous systems to tightly regulate
extracellular serotonin levels presents challenges for detection (vide supra). The
likely consequence of this are endogenous extracellular serotonin concentrations
that are much lower than dopamine levels (Figure 2.1C) (Shen et al., 2004). To
date, 15 serotonergic receptors have been identified that precisely and rapidly
control serotonin (Nautiyal & Hen, 2017; Jennings, 2013). In addition, multiple
mechanisms influence serotonin reuptake including promiscuous reuptake of
serotonin by other monoamine transporters (e.g. dopamine transporters (DATs),
norepinephrine transporters (NETs) and organic cation transporters (OCTs)),
other than SERTs (Baganz et al., 2008; Daws, Toney, Gerhardt, & Frazer, 1998).
Further highlighting the sheer intracy of this system, significant control of
serotonin reuptake is implemented by serotonin autoreceptors that are G-protein
coupled to SERTs. (Montañez, Munn, Owens, Horton, & Daws, 2014; Murphy et
al., 2003). To even further obstruct measurements, serotonin metabolites of
similar chemical structure can be nearly 500 times more concentrated than
serotonin itself (Hashemi et al., 2009), indicating a rapid rate of metabolism. Not
only does this fast metabolism reduce the time during which serotonin is
detectable, some metabolites have been shown to dramatically degrade the
integrity of microelectrode detection probes (Hashemi et al., 2009). Together,
these circumstances complicate both the measurement and understanding of
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serotonin in vivo and ultimately how serotonergic activity corresponds to
behavior.

2.1d Measurement of Serotonin In Vivo
Active neurochemical signal delivery relies on sub-second chemical exchange.
Thus,

to

define

serotonin

neurotransmission,

high

temporal-resolution

measurement is critical. Traditional microdialysis has formed our current
apprehension of overall serotonergic activity (for example: Yang, Thompson,
McIntosh, Altieri, & Andrews, 2013; Volle et al, 2018). Microdialysis has low
detection limits when coupled to efficient analytical techniques for separation,
detection, and quantification of analytes (e.g. ultrahigh-performance liquid
chromatograph and electrochemical detection) (Liu et al., 2010). However,
disadvantages such as temporal resolution (> 1 minute) and damage of tissue
surrounding the large probe (approximately 200 um) have created a large body
of contradictory results (Chefer, Thompson, Zapata, & Shippenberg, 2009;
Jaquins-Gerstl & Michael, 2015). Consequently, measurement tools for this
analyte that operate at high time resolution with minimal tissue damage are
highly desired. Notably, an electrochemical technique called chronoamperometry
has been employed previously by Daws and colleagues to explore SERT
mechanisms under varying experimental conditions (e.g. genetically-modified
animal models and pharmacological manipulations) primarily in the hippocampus
(Montanez et al., 2014; France et al., 2009; Daws et al., 2005). These
experiments have greatly improved our understanding of the SERTs and their
rate of serotonin clearance. However, this technique typically requires exogenous
13

application of serotonin (Daws, Toney, Davis, Gerhardt, & Frazer, 1997) and the
external source of serotonin has been thought to cause rapid physiological
changes in SERT expression (Daws & Toney, 2007).
FSCV has become one of the most powerful analytical techniques to study
neurotransmitter release and reuptake in vivo due to its small probe size (6 um)
and high selectivity, sensitivity (nM), and temporal resolution (10 Hz). Since the
development of FSCV by Ralph Adams in the 1980’s, numerous seminal
discoveries have been made on dopamine’s role in learning and motivation using
this technique (e.g. Phillips et al., 2003; Flagel et al., 2011; Cheer et al., 2007).
More recently, serotonin FSCV measurements have been established in
anesthetized rodents and are just beginning to unearth the dynamics and the
sheer complexity of serotonin’s in vivo actions.

Figure 2.1. Challenges of measuring serotonin. (A) Histology from the lab
showing the experimental targeting of the dorsal raphe nucleus at a 30-degree
angle. (B) The dorsal raphe nucleus is non-homogenous, shown by the
heterogeneous innervation of the ventral tegmental area (VTA). Data adapted
from Qi et al, 2014. (C) Neurotransmitter content in the whole rat brain (adapted
from Zhu et al., 2011) and specific regions. *data obtained from the lab;
unpublished results from Botterblom & Feenstra.
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In the next section, general electrochemistry principles governing the
dynamics of sub-second FSCV neurotransmitter sampling are described. The
contributions of this technique to furthering our understanding of in vivo serotonin
fluctuations are highlighted and novel frontiers in other electrochemical
methodologies are explored.

2.2 FSCV: General Principles
FSCV is an analytical tool that takes advantage of thermodynamic and
electrochemical phenomena to govern subsecond measurements. Small,
positively charged ions such as dopamine and serotonin are attracted to a
negatively charged carbon-fiber microelectrode (CFM) surface during a short
holding period (typically 100 ms). Then an analyte specific waveform, which is
tailored to induce electron transfer via oxidation and reduction of the ion, is
applied to the CFM. The oxidation and reduction occur at discrete potentials and
are measured as current vs. potential to obtain a cyclic voltammogram (CV). The
CV acts as an electrochemical “stamp” and is used to qualify and quantify the
analyte (Phillips & Wightman, 2003).
Besides its advantages in time resolution and small probe size, selectivity
can be a concern in any analytical measurement. In FSCV, two primary intrinsic
chemical properties can be exploited to provide selectivity; analyte electron
transfer kinetics and the charge on the ion. Depending on the ion of interest a
combination of approaches can be taken that take into account charge and
electron transfer kinetics of the analyte of interest vs. those of interferences. This
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is illustrated below by using dopamine and serotonin detection, respectively, as
examples.

2.2a Selectivity of Dopamine Detection
For FSCV dopamine measurements, it is well known that ascorbic acid (AA) is
the primary interferent. However, the high ambient levels of ascorbic acid in the
brain (McIlwain, Thomas, & Bell, 1956; Schenk, Miller, Gaddis, & Adams, 1982)
should not interfere with the signal because FSCV is background subtracted.
Nonetheless, AA may reduce the sensitivity of the electrode to dopamine if
adsorption sites on the CFM are blocked by AA. More significantly perhaps is
that AA is released upon glutamate reuptake (Cammack, Ghasemzadeh, &
Adams, 1991) since FSCV stimulations will release both dopamine and
glutamate. Thus, AA is likely to be transiently released during FSCV file
collection. As discussed above, selectivity can be garnered by utilizing
differences in electron transfer kinetics and ionic charge. In solution, ascorbic
acid is negatively charged and dopamine is positivity charged, and the electron
transfer kinetics of AA oxidation are significantly slower vs. dopamine oxidation
(Wightman, May, & Michael, 1988). Therefore, if between scans the electrode is
held at a negative potential and a fast enough scan rate is applied, then AA is
repelled during scans and does not have an opportunity to transfer electrons to
the CFM during the scan. This effect can be potentiated if the CFM surface is
‘activated’ prior to analysis. Activation refers to oxidation of the surface by heat,
electrochemistry or chemical treatments (Heien, Phillips, Stuber, Seipel, &
Wightman, 2003; Strand & Venton, 2008). This activation procedure deposits a
16

high density of negatively charged oxygen moieties on the electrode surface,
thus increases the extent of AA repulsion and actually facilitates dopamine
preconcentration. Surface oxidation has a further advantage when performed
electrochemically during each scan (i.e. scanning up to 1.3 V). At 1.3V, carbon
itself is oxidized and a monolayer of carbon is lost from the CFM surface,
essentially providing a fresh electrode for the next measurement (preventing
irreversible fouling) (Takmakov et al., 2010; Mitchell, Dunaway, McCarty, &
Sombers, 2017).

2.2b Selectivity of Serotonin Detection
The biggest challenge for selective serotonin measurements is interference by
dopamine given the mutual presence of both these neuromodulators in many
parts of the brain and their similar chemical properties. The transfer kinetics of
serotonin electro-oxidation are more rapid vs. dopamine, consequently sensitivity
to dopamine can be reduced by increasing scan rate to 1000 V s -1 (Figure 2.2A).
An additional phenomenon that helps here is that the serotonin adsorption
equilibrium onto the CFM is more favorable than dopamine’s adsorption. This
effect means that the resting potential between scans can be kept at a positive
potential which, in addition to scanning faster, significantly diminishes the FSCV
response to dopamine. The main metabolite of serotonin, 5-Hydroxyindoleacetic
acid (5-HIAA) is not thought to be a significant interference since there is no
evidence that it is transiently released, however 5-HIAA is problematic for
electrode fouling (Hashemi et al., 2009). Electrode fouling is the accumulation of
undesired material on the carbon-fiber surface that is detrimental to the
17

electrode’s function, therefore adjustments in the FSCV detection scheme is
necessary to exclude the influence of this metabolite on the CFM. These are
discussed in the following section.

2.3 Serotonin FSCV
The first report of serotonin FSCV in vivo was an experiment in which dopamine
was depleted from dopamine neuron terminals in the striatum via inhibition of Laromatic acid decarboxylase. These neurons were then loaded with serotonin by
a means of tryptophan loading, promoting electrically evoked serotonin release
(Stamford, Kruk, & Millar, 1990). This experiment, although elegant, was not
indicative of the endogenous function of the serotonin system and the detection
scheme utilized did not allow for discrimination between serotonin and dopamine.
Additionally,

serotonin

electro-oxidation

produces

several

intermediary

monomers that rapidly polymerize on the electrode to create a ‘film’ covering the
electrode. It is known that such an electrode ‘fouling’ significantly lowers
electrode sensitivity. Later, the development of the ‘Jackson Waveform’
(Jackson, Dietz, & Wightman, 1995) significantly improved detection selectivity
and electrode fouling:
1) to distinguish between dopamine and serotonin 1000 V s -1 is utilized
and the electrode is held at a positive resting potential
2) to reduce the fouling effects of serotonin electro-polymerization on the
CFM, the CFM is held at 0.2 V between scans, which abolishes the
production of the the major electro-oxidation product. 1000 V s-1 also
appears to reduce the production of these side products.
18

The Jackson waveform was subsequently utilized in tissue slice
preparations to study serotonin dynamics in different brain regions and under
SSRI treatment (Figure 2.2A) (Bunin & Wightman, 1998; Bunin, Prioleau,
Mailman, & Wightman, 1998). The ‘Jackson Waveform’ was a breakthrough for
real-time serotonin measurements, however, the waveform alone did not lead to
successful measurements of evoked serotonin in vivo. In 2009, the reason for the
lack of success for in vivo measurements was discovered by Hashemi et al.,
2009. One major difference between measurements in slice preparations and in
vivo is the large ambient concentration of 5-HIAA in vivo. As previously
mentioned, it is not likely that 5-HIAA would act as an interference, however, it is
structurally very similar to serotonin and exerts similar fouling effects on the
CFM. Given that it is 100-1000 times more concentrated in the extracellular
space in vivo (in slice preparations it washes out), it rapidly and profoundly fouls
the CFM as it is positioned in the brain in vivo. (Hashemi et al., 2009). In solution,
5-HIAA is negatively charged while serotonin is positively charged. Thus, a new
protocol was developed to selectively repel 5-HIAA by depositing Nafion onto the
carbon fiber surface at an advantageous and controlled thickness (Brazell et al.,
1987; Rice & Nicholson, 1989). An unwanted side effect of Nafion application is
that applied films that are too thick (1-3 um) lead to a significant decrease in
electrode response times, whereas a layer that is too thin will not perform
efficiently to repel 5-HIAA and fouling will occur (Nagy et al., 1985). The ideal
thickness is about 300 – 350 um, as modeled and described in detail in Hashemi
et al., 2009. After coating the CFM with Nafion, the microelectrode is nearly 200
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times more sensitive to serotonin than 5-HIAA because of the pre-concentration
of the positively charged serotonin ions trapped in the Nafion membrane,
permitting in vivo measurements to be performed (Gerhardt, Oke, Nagy,
Moghaddam & Adams, 1984; Hashemi et al., 2009). A scanning electron
microscope (SEM) image of a Nafion-coated CFM is shown in Figure 2.2B.
Nafion is not useful with waveforms that apply potentials > 1.0 V (i.e., dopamine
waveform) due to the oxidation of the monolayer of the CFM during each scan as
previously described which destabilize the Nafion layer. Potential disadvantages
of the Nafion technique is the unequal coverage of the CFM and greater
electrode variability, however strict adherence to the described electrodepositing
procedure has can limit variability.

Figure 2.2. Detection of serotonin
using fast-scan cyclic voltammetry.
(A) A serotonin-selective waveform is
applied
to
the
carbon-fiber
microelectrode to promote the oxidation
and reduction of serotonin, which is
measured as current and is proportional
to the serotonin molecules near the
electrode. (B) Nafion-coated carbon-fiber
microelectrodes are required to repel
interfering metabolites (5-HIAA) and
enhance serotonin sensitivity. Adapted
with permission from Hashemi et al.,
2009.
Copyright
2009
American
Chemical Society. (C) Representative
serotonin color plot and identifying cyclic
voltammogram.
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2.3a General Findings of Serotonin FSCV
Although serotonin neurons project widely across the mammalian brain, it is not
known whether serotonin signaling is uniform throughout the brain or whether
regional specificity exists. It is generally postulated that deficits in serotonin
neurotransmission can contribute to a number of psychiatric disorders including
depression, anxiety, and obsessive-compulsive disorder (OCD). As such,
selective-serotonin reuptake inhibitors (SSRIs) were developed in the late 70s
(Fuller et al., 1974; Fuller, & Wong, 1977), which aim to increase extracellular
serotonin levels by inhibiting SERTs. Clinical success of SSRIs in the abovementioned disorders (for which SSRI are one of the primary pharmacological
treatments) is inconsistent. This irregularity in therapeutic relief may be due to
regional differences in serotonin release and reuptake, whereby SSRI-induced
global increases in extracellular serotonin availability and signaling may not be
useful for therapeutic purposes. Alternatively, SSRI may have different regional
effects on serotonin release and reuptake that is otherwise not distinguishable.
Therefore, irregularity in therapeutic relief may be better understood by studying
in vivo regional serotonin dynamics with FSCV. Finally, even in the case of
regional uniformity, FSCV measurements may be necessary to uncover SSRI
effects on the sub-second level. Although serotonin FSCV is a young field, this
section highlights the contributions this method is making to broadening our
knowledge of serotonin dynamics in different brain regions.
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Substantia Nigra, Pars Reticulata (SNR)
To date, most FSCV measurements of serotonin have been performed in the
SNR where serotonin terminals are the most concentrated of all brain regions
(Palkovits, Brownstein, & Saavedra, 1974; Reubi & Emson, 1978). In 2009, the
first paper reporting in vivo serotonin measurements in the SNR via DRN
stimulation was published (Hashemi et al., 2009). As mentioned above,
physically targeting the DRN is technically difficult and results in low success
rates. In a follow up study, serotonin release in the SNR was observed by
stimulating the medial forebrain bundle (MFB), an anatomically easier surgical
target located anterior to the terminal release site. Due to the posterior position of
the CFM with respect to the stimulating electrode, this suggested serotonin fibers
could be retrogradely activated (Hashemi et al., 2011).
The stimulation of MFB yields three distinct serotonin response profiles –
fast, slow and hybrid based on their clearance slopes (Wood et al., 2014). As the
name suggests, fast and slow response profiles show fast and slow serotonin
clearance times (approximately 8s vs. 30s, respectively). The hybrid response
profile is a mixture of the two and displays a fast decay to clear serotonin for a
couple seconds then switches to a slow decay. Mathematical modelling of these
responses revealed that two reuptake mechanisms – one high affinity, low
efficiency system, termed Uptake 1 and mediated by SERTs and one low affinity,
high efficiency system, facilitated by monoamine transporters other than SERTs,
including DATs, NETs and OCTs. It is likely that at low extracellular
concentrations, Uptake 1 by SERTs (high affinity, low efficiency) is efficient,
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however at higher concentrations, serotonin may diffuse to other transporters
(DATs, NETs, and OCTs) and be reuptaken by Uptake 2 mechanisms (low
affinity, high efficiency). A common feature of all stimulated serotonin release is
that the serotonin concentration ‘dips’ below the baseline after concentration
levels return to baseline. Thus, an autoreceptor effect (7 seconds after the
beginning of the stimulation) was incorporated into the model to account for this
dip below baseline. Methiothepin, a non-selective serotonin receptor antagonist
with a high affinity for serotonin autoreceptors, (Monachon, Burkhard, Jalfre, &
Haefely, 1972) eliminates this dip below baseline, indicating that serotonin
autoreceptors may act to reduce serotonin transmission within the time frame of
the FSCV collection window (30s) (Barnes & Sharp, 1999; Wood et al., 2014).
These findings support prior hypotheses on Uptake 1 and Uptake 2 in
synaptosomes (Shaskan & Snyder, 1970; Daws, Koek, & Mitchell, 2013).
Multiple reuptake mechanisms and the prolonged autoreceptor control of
serotonin support the notion that serotonin a highly regulated system.
SSRIs acutely act on the SERTs to inhibit the reuptake of serotonin,
however, therapeutic relief in psychiatric patients may not be achieved until
several weeks of chronic administration (Gelenberg & Chesen, 2000). After an
acute dose of the SSRI Escitalopram (Lexapro; 10 mg kg-1 i.p.), FSCV
measurements of serotonin showed immediate dynamic neurochemical changes
through the rapidly augmented release of serotonin and gradual increase in
clearance time (t1/2) over 2 hours (Wood & Hashemi, 2013). The t1/2 was
positively correlated to an increasing dose of Escitalopram (1, 10, 100 mg kg -1)
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while the amplitude was impacted the most by the middle dose (10 mg kg -1),
similar to previous observations of DAT inhibition (Song et al., 2012).
Alternatively, tissue slice preparations report only a modest increase of serotonin
release (~10%), indicating that synaptic processes found in vivo additionally
modulate SSRI mechanisms (Bunin & Wightman, 1998). Due to the increase in
clearance time up to 120 minutes after an acute SSRI administration in vivo, it is
highly likely that SSRIs cause dynamic physiological changes outside of their
accepted mode of action for longer-term therapeutic benefits.
Another important study compared the regulation of serotonin in the SNR
to dopamine in the nucleus accumbens. Overall, it was found that serotonin
transmission is most sensitive to uptake and metabolic mechanisms, while
dopamine is dependent on synthesis and repackaging (Hashemi et al., 2012).
The response profile of serotonin was shown to be much broader than dopamine,
with measurable release occurring at a MFB stimulation depth of 7.0-10.0 mm
below dura, compared to 8.0-9.0 mm for dopamine, supporting the known, wide
innervation of the brain by serotonin.

Hypothalamus
The hypothalamus is an important structure, amongst others that comprise the
limbic system and contains relatively high levels of serotonin (see Figure 2.1C;
unpublished data from Feenstra & Botterblom). The premammillary nucleus (PM)
is an interesting hypothalamic structure in that it contains high levels of both
serotonin and histamine. Histamine had been thought to modulate serotonin
transmission due to the presence of inhibitory H3 heteroreceptors on serotonin
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terminals (Threlfell et al., 2004; Fink, Schlicker, Neise, Gothert, 1990). The effect
of histamine on serotonin in the PM was studied in recent work via development
of an FSCV method that simultaneously measures serotonin and histamine
(Samaranayake et al., 2016). An anterior region of the MFB, containing fewer
serotonin axons, (Nieuwenhuys, Geeraedts, & Veening, 1982) was stimulated.
This stimulation evoked histamine, but not serotonin in the PM such that
modulation of ambient, not evoked, serotonin could be investigated. A potent and
rapid inhibition of serotonin was observed in response to histamine release.
(Samaranayake et al., 2016). A dose response for thioperamide (2, 20, and 50
mg kg-1), a histamine receptor (H3) antagonist, was carried out and the
corresponding histaminergic and serotonergic responses were mathematically
modeled. Overall, it was shown that the potent inhibition of serotonin by
histamine in the PM is indeed mediated by H3 heteroreceptors on serotonergic
neurons. This finding supports previous speculations that H3 receptors on
serotonin terminals (Schlicker, Betz, & Gothert, 1988; Esbenshade et al., 2008)
inhibit serotonin transmission (Threlfell et al., 2004). Due to the hypothalamus’
crucial role of regulating stress hormones, it is important to understand the
neurochemical influence this region has on other neuromodulators, such as
serotonin, to better understand how to better maintain stress levels and promote
healthy individuals.

Cortex
The medial prefrontal cortex (mPFC) has a relatively high serotonin content and
has been shown to have broad influence on cognitive control and modulating
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social behavior (see Figure 2.1C; unpublished data from Botterblom & Feenstra)
(Miller & Cohen, 2001). In 2018, two serotonergic release events corresponding
to a single stimulation of the MFB was observed for the first time using FSCV in
mice (West et al., 2018). The two responses were related to distinct reuptake
profiles encompassing both Uptake 1 and 2 mechanisms, as previously
described in the SNR. Through pharmacology, histology, and mathematics, it
was found that different subsets of serotonin axons transverse the MFB and
terminate in separate domains with distinct reuptake responses in separate
cortical layers. This study supports the idea of intricacy of serotonin
neurotransmission and presents evidence of a highly elaborate biochemical
organization of serotonin in the mPFC.
Serotonin FSCV measurements have also been made in layer 1 of the
somatosensory cortex in mice, which is important for processing all sensory
information (Jain, Qi, Collins, Kaas, 2008). This study revealed that serotonin
neurons have a unique capability to undergo regrowth and gain of function
following damage produced by a systemic amphetamine lesion or local stab
lesion (Jin et al., 2016). Serotonin release was evoked by MFB stimulation and
measured 1 week, 3 months, and 6 months after amphetamine treatment. No
evoked serotonin release was recorded 1 week and 3 months post-lesion,
however, by 6 months, a recovery in serotonin activity was apparent in
comparison to controls (11.9 + 2.9 nM vs. 14.5 + 8.3 nM, respectively).
Behavioral tests displayed similar results, with the recovery of their behavioral
measures occurring only 6 months after an amphetamine lesion. Two-photon
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microscopy images showed new serotonergic axon growth after 3 months,
however, it was speculated that they may need further maturation to function.
Overall, this study showed that a large percentage (>80%) of damaged serotonin
axons are susceptible to new growth and recovery of functionality. Two possible
explanations for this phenomena were given:
1) since serotonergic axons rely on slow, diffuse volume transmission
rather than fast-localized synaptic transmission (Hornung, 2003;
DeFilipe & Jones, 1988), their regrowth is more relaxed and allows for
an approximate former position to be adequate
2) serotonin axonal growth cones fail to receive stop signals from the
tissue matrix.
Understanding the biochemical organization and corresponding serotonergic
function of the cortex will lead to invaluable information on cortical plasticity and
how to assemble neural connections that promote beneficial decisions and social
behavior.

Dorsal Raphe Nucleus (DRN)
High-frequency electrical deep brain stimulation (DBS) is becoming a more
common treatment for clinicians to alleviate depression and compulsive
symptoms in psychiatric patients (Holtzheimer & Mayberg, 2011; Srejic et al.
2014), however, the mechanisms underlying the effects of this approach is not
well understood. A recent study by Srejic et al. showed that high frequency
stimulation (HFS) of the mPFC resulted in a similar amplitude of serotonin
release as a typical short train simulation, however, a more pronounced decay of
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the

extracellular

serotonin

concentration

was

evident,

suggesting

an

enhancement of reuptake (Srejic, Wood, Zeqja, Hashemi, & Hutchinson, 2016).
The enhancement of serotonin reuptake induced by HFS is speculated to be
facilitated by an upregulation or modification of the affinity of SERTs (Zhu et al.,
2010; Baganz & Blakely, 2012). Additionally, this could be explained by activitydependent endocytosis, in which rapid endocytosis can be activated by intense
stimulation (or exocytosis) when neurotransmitter recycling needs to be
accelerated to restore vesicle storage (Klingauf, Kavalali, & Tsien, 1998; Sara,
Mozhayeva, Liu, & Kavalali, 2002). These two potential explanations may serve
as homeostatic synaptic mechanisms to maintain extracellular serotonin at
control levels after HFS, which is in agreement with the previously observed tight
regulation of serotonin in vivo (Hashemi et al., 2012). Due to presence of
serotonergic cell bodies in the DRN, this region is of interest for the treatment of
many psychiatric disorders by a means of globally impacting serotonergic
circuitry throughout the brain.
It is important to note that these findings would not be possible with a
slower sampling technique such as microdialysis because of the required hightemporal and spatial resolution that FSCV provides. Studies are ongoing to
understand the biochemical arrangement of serotonin, how it is influenced by
other neuromodulators, and why SSRIs are variable and delayed in their efficacy,
in a bid to improve these therapies.
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2.3b FSCV Disadvantages
Although FSCV serotonin measurements provide invaluable information about
serotonin release and reuptake under different experimental conditions and
diseases, there are still substantial limitations for FSCV in investigations of
serotonin. First, all of the aforementioned experiments have been conducted in
anesthetized rodents. This has prevented a detailed understanding of serotonin
activity linked to behaviorally relevant environmental stimuli and corresponding
behavior. Second, FSCV is reliant on background subtraction thus electrical,
chemical or behavioral stimuli are required to provoke release (Howell, Kuhr,
Ensman, & Wightman, 1986). The fast-scan rates employed in FSCV lead to high
“background” currents, thereby requiring the removal of the charging current to
reveal small, faradaic currents produced by monoamines of low concentration
and limiting FSCV measurements to changes in concentration. Third, electrical
stimulation is non-selective and affects numerous neurotransmitters and
neuronal targets. Furthermore, to evoke serotonin release, a powerful electrical
stimulation must be employed (Hashemi et al., 2011; Robinson, Venton, Heien, &
Wightman, 2003), which raises questions of physiological relevance and potential
tissue damage upon repeated stimulation. Fourth, since FSCV relies on eliciting
a change in concentration, ambient measurements could not traditionally be
made to understand neurotransmitter basal activity. It is especially important to
understand ambient, or tonic serotonin levels on a rapid timescale because
serotonin axons are thought to primarily rely on slow, diffuse volume
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transmission rather than fast, localized synaptic transmission (Hornung, 2003;
DeFilipe & Jones, 1988).

2.3c Novel Frontiers in Tool Development for the Investigation of Serotonin
Novel

technological

advancements

have

been

made

to

promote

the

understanding of serotonin in vivo. Developing optogenetic control of
serotonergic neurons has become a major point of interest to combat the
problem of non-selective electrical stimulation (McElligott, 2015). The first study
that combined serotonergic FSCV measurements to optogenetic stimulation in
vivo was performed in drosophila and showed that low-frequency stimulations of
serotonin induce a steady-state response in comparison to high-frequency
stimulation-induced peak responses (Xiao, Priyman, & Venton, 2014). Behavioral
studies have also implemented optogenetic control of serotonin, primarily in
mice. However, neurochemical readouts by FSCV have not been reported at this
point. Some of these studies have indicated serotonin may be a key regulator of
patience/waiting, due to the activation of serotonergic neurons corresponding to
mice waiting longer for future rewards (Miyazaki K., Miyazaki K.W., & Doya,
2012; Miyazaki K.W., Miyazak K., & Doya, 2012, 2014; Fronseca, Murakami, &
Mainen, 2015). With the intention of translation to the clinics, a proof-of-principle
study

using

a

system

called

Wireless

Instantaneous

Neurotransmitter

Concentration System (WINCS) was performed in DRN rat brain slices to
measure serotonin with FSCV (Griessenauer et al., 2010). WINCS is a small,
sterilizable, wireless data acquisition component designed in compliance with
FDA standards for medical electrical device safety. Most recently, steps have
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been taken to mathematically decipher in vivo signals, thought to contain a
serotonergic component, obtained in Parkinson’s patients who received DBS
electrodes and performed an investment task (Moran et al., 2018).
Although all of these studies are advancing the methods in which
serotonin can be measured and manipulated, there is still fundamentally a lack in
our knowledge of the magnitude of ambient extracellular serotonin levels. A new
technique, termed fast-scan controlled-adsorption voltammetry, has been
recently developed to help fill this gap on a rapid time scale.

2.4 Fast-Scan Controlled-Adsorption Voltammetry (FSCAV)
FSCAV is a cutting-edge voltammetric technique that enables quantitative
ambient in vivo neurotransmitter measurements (Atcherley, Wood, Parent,
Hashemi & Heien, 2015). FSCAV reports basal neurotransmitter concentration
over a 10 second period and can be performed in less than 20 seconds
(Atcherley et al., 2013; Atcherley et al., 2015; Burrell, Atcherley, Heien, & Lipski,
2015). An advantage of coupling FSCAV to existing FSCV systems is the
production of a current versus voltage plot (CV), which, as described above is an
essential process to identify analytes of interest (thereby also implicitly testing
functionality of the electrode and its placement). Consequently, FSCAV
experiments have thus far been initiated with FSCV to optimize the location of
the CFM in a brain locale rich in the analyte of interest.
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FSCAV measurements are performed in a three-step procedure. Step 1:
an analyte-specific waveform is applied to the CFM at a high frequency (100 Hz)
and scan rate (1200 V/s) to minimize adsorption to the CFM for 2 seconds,
allowing for a response that is not governed by neurotransmitters (i.e. providing a
background). Step 2: a constant potential (the analyte-specific holding potential)
is then applied for 10 seconds to allow the neurotransmitter to pre-concentrate
around the electrode and adsorb to the CFM, reaching a coverage density in
equilibrium with the surroundings. Step 3: the same waveform used in step 1 is
reapplied to the CFM and the adsorbed neurotransmitter is measured with FSCV
in respect to the first two seconds of the data collection file (background). These
steps can be visualized in Figure 2.3A. The signal obtained from FSCAV has
been shown to be dependent on both mass transfer and adsorption dynamics,
which determine the time required to reach equilibrium in step 2 (Atcherley et al.,
2013).

Figure 2.3. Overview of fast-scan controlled-adsorption voltammetry. (A) A
visual representation of the three step process: 1) minimized adsorption; 2)
equilibrium; 3) adsorption electrochemical measurement. The presence of the
neurotransmitter near the carbon-fiber microelectrode, the potential application,
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and surface-accumulated dopamine (rDA) are displayed top to bottom. (B) Color
plot obtained from the measurement in step 3. (C) Representative current trace
(red) 10 ms after the start of step 3 and representative integration limits used for
data analysis. (D) A necessary post-implantation calibration plot. Reproduced
from Atcherley et al., 2015 with permission from The Royal Society of Chemistry.
In order to perform FSCAV, an additional piece of equipment, a digital
switch, must be fabricated in-house and incorporated into existing FSCV
systems. This switch employs an operational amplifier (op amp) coupled to a
transistor-transistor logic (TTL), which enables the system to precisely and
rapidly alter between applying a FSCV waveform and a constant potential from
an external power source to the working electrode (Atcherley et al., 2013).
FSCAV can easily be employed through FSCV software (WCCV or Demon
Voltammetry, for example) using the stimulation settings. After file collection,
data analysis is executed by integrating the first resulting CV of the analyte of
interest during step 3. A representative color plot for the ambient measurement of
dopamine is shown in Figure 2.3B. It is important to note that the firstbackground subtracted CV becomes visible on the 2 nd or 3rd scan after the
waveform is re-applied following the constant potential of 10s, due to stray
capacitance from the switching component when altering between the constant
potential back to the waveform. To remove this large interfering background
charge, convolution theory can be utilized (Oldham, 1986; Atcherley et al., 2013,
2014). Due to electrode variability, integration limits need to be set intuitively in
vivo due to the complex matrix of the brain and additional analytes that are
present around the electrode (Cahill et al., 1996; Heien, Johnson, & Wightman,
2004; Takmakov et al., 2010b). Most commonly, using current vs. time traces,
the integration limits are set by placing both initial and final limits at the local
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minima and encompassing the entire oxidation peak of the analyte (as seen in
Figure 2.3C). The resulting area will be calculated as charge (pC) and plotted vs.
serotonin concentration. Post-implantation calibration plots are then created and
utilized to report in vivo concentrations (Figure 2.3D). Post-calibration of each
electrode

is

necessary

to

reliably

measure

and

quantify

absolute

neurotransmitter concentrations, due to the electrode variability (vide supra) and
ongoing structural changes to the CFM (due to activating potentials > 1.0 V for
instance) that is encountered in traditional FSCV. A disadvantage to this is that
lesions cannot be made to histologically identify the CFM placement since the
electrode needs to remain intact for post calibrations.
FSCAV was first established for dopamine measurements in vivo in 2015
and demonstrated it could become a powerful tool used in parallel with FSCV to
disclose both the phasic and tonic changes in neurotransmitters at a single
sensor (Atcherley et al., 2015). In 2016, FSCAV was used to record unbound
Cu2+ in various complex matrices, supporting the ability of FSCAV to and reliably
perform selective measurements of analytes of interest in numerous fields
(Pathirathna, Siriwardhane, McElmurry, Morgan, & Hashemi, 2016). More
recently, ambient measurements of serotonin have been conducted to better
understand absolute extracellular concentrations of serotonin (Abdalla et al.,
2017; see below).

2.5 Measurement of the Ambient Extracellular Concentration of Serotonin
In 2017 ambient measurements of serotonin were established using FSCAV
(Abdalla et al., 2017). The waveform employed is the above-mentioned Jackson
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waveform (0.2V to 1.0V to -0.1V to 0.2V; scan rate of 1000 V/s) with a
supplementary controlled-adsorption period (10s) of a 0.2 V constant potential.
The third scan after the controlled-adsorption period was extracted for data
analysis and the integration limits are set approximately from 0.4V to 0.85V,
encompassing the oxidation peak of serotonin.
This study reported mouse CA2 hippocampus basal concentration as 64.9
+ 2.3 nM (Figure 2.4). In comparison, previous microdialysis studies have
suggested serotonin levels are in a lower nanomolar range (Mathews et al.,
2004; Zhang et al., 2013; Lee et al., 2016). However, FSCAV measurements are
performed on an entirely different spatial scale due to the fundamentally different
dimensions of the two probes. Additionally, in FSCAV, the electrode’s position is
optimized with FSCV and thus located in a “hot spot”, or where there is high
serotonin activity, which may account for the higher reported serotonin levels.
After determining basal serotonin levels, the study verified the selectivity of the
signal in vivo via pharmacology and mathematics. Results showed no
interference by 5-HIAA, dopamine, or norepinephrine at physiological conditions.
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Figure 2.4. Ambient measurement of serotonin using fast-scan controlledadsorption voltammetry. (A) Representative color plots of serotonin in vivo (i)
and in vitro (ii). (B). Cyclic voltammograms extracted from the 3rd scan during
step 3 in (A), shown by dashed, white lines. The inset displays individual (grey)
and averaged (orange) ambient serotonin recordings from the mouse CA2 region
of the hippocampus. Reprinted with permission from Abdalla et al., 2017.
Copyright 2017 American Chemical Society.

The development of FSCAV for serotonin enables the first robust, and
high-temporal resolution measurements of serotonin’s basal concentrations.
Coupling FSCAV to FSCV recordings provides a novel platform to acquire a
deeper chemical understanding of serotonin activity at a single sensor.
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CHAPTER 3
A SIMPLIFIED LED-DRIVEN SWITCH FOR FAST-SCAN
CONTROLLED-ADSORPTION VOLTAMMETRY
INSTRUMENTATION2

2

Robke, R., Hashemi, P., and Ramsson, E. Under Review in HardwareX,
05/11/2018.
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Abstract:
Fast-scan cyclic voltammetry (FSCV) is an analytical tool used to probe
neurochemical processes in real-time. A major drawback for specialized
applications of FSCV is that instrumentation must be constructed, or modified, inhouse by those with expertise in electronics. One such specialized application is
the newly developed fast-scan controlled-adsorption voltammetry (FSCAV), that
measures ambient in vivo dopamine and serotonin. FSCAV requires additional
equipment, an operational amplifier coupled to a transistor-transistor logic, which
was originally termed ‘the switch’, allowing the system to alter between applying
a FSCV waveform and a constant potential from an external power source to the
working electrode. To facilitate the integration of FSCAV into existing FSCV
instruments by making this method more accessible to the community, in this
paper we design a simplified switching component. Specifically, we employ two
light emitting diodes (LEDs) to generate the voltage needed to drive a NPN
bipolar junction transistor, substantially streamlining the circuitry and fabrication
of the switching component. In vitro and in vivo analyses are performed and
compared between the new LED circuit vs. the original switch, showing good
agreement. Thus, we present a new, simplified scheme to perform FSCAV that is
cheap, simple, and easy to construct by a non-expert.

Keywords:

Dopamine,

fast-scan

cyclic

instrumentation, component
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voltammetry,

ambient,

circuit,

Figure 3.1 LED circuit graphical abstract.

3.1 Hardware in Context
Fast-scan controlled-adsorption voltammetry (FSCAV) is a newly developed tool
that is coupled to existing fast-scan cyclic voltammetry (FSCV) systems to
measure ambient neurotransmitter concentrations. FSCAV necessitates a
custom made component, termed the switch, utilizing an operational amplifier
coupled to a transistor-transistor logic, which may be challenging to those without
prior experience in electronics. Here, a simplified component, a LED circuit,
employs two light emitting diodes (LEDs) to generate the voltage needed to drive
a NPN bipolar junction transistor in a straightforward manner. Hardware
specifications are shown in Table 3.1.

39

3.2 Hardware Description
The LED circuit achieves optical isolation of the signal by placing two infrared
(890nm; 4V forward voltage) LEDs facing one another. Stimulation outputs are
set at 4V. For digital or TTL pulses, a voltage divider can drop the 5V to the
necessary 4V, as shown in Figure 3.2A (R1 = 10 kOhm; R2 = 40 kOhm, for
instance). The light from L1 will illuminate L2 and cause ~0.9V to be generated at
L2. This is enough to power the base of the NPN BJT transistor and allow the 0.4V to pass. The output of the circuit is connected to the recording electrode,
and when the -0.4V is allowed to pass, it clamps the recording electrode at -0.4V.
The original switch used for FSCAV was constructed in-house and
connected to existing FSCV systems as an extension of the ‘breakout box’ with
four connections to an external power supply. The switch utilizes an op amp
coupled to a TTL, enabling the system to apply the constant potential from the
external power source (-0.4 V delay). This allows the user to transition between
FSCV and FSCAV, from stimulation to a constant potential, respectively
(Atcherley et al., 2013).
Those without prior electronics training my find it challenging to construct the
original switch. The new LED circuit described here requires just two infrared
LEDs and one NPN transistor, enabling this alternative to be cost-effective and
simple to construct with a basic understanding of soldering principles. The LED
circuit requires the addition of the external -0.4V power supply through one
connection, enabling a direct voltage clamp. Additionally, if older FSCV systems
are utilized, this -0.4V can come from 6052 or 6052e National Instruments cards.
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The ability to integrate the LED circuit into older FSCV systems is an additional
advantage of this circuit. The bill of materials can be seen in Table 3.2.
General points:


The LED circuit is a simplified, cheaper version of the original switch
utilized in FSCAV



The LED circuit can be easily coupled to older FSCV existing systems



Using the LED circuit, ambient neurotransmitter concentrations can be
measured with high temporal resolution

3.3 Build Instructions


Wire the components as shown in the schematic in Figure 3.2A.



LED1 (L1) will receive 4V to the anode from a TTL or National
Instruments card 6052 (6052E) via a female BNC connector. If
receiving 4V from a TTL, a voltage divider is used to drop the voltage.
R1 = 10 kOhm; R2 = 40 kOhm. The cathode is connected to ground.



The anode of L2 is connected to the base of the NPN transistor. The
emitter is connected to both the cathode of L2 and an alligator clip or
terminal. In Figure 3.2B, screws are used as simple terminals, so the 0.4 V input and Working Electrode output are wired to screws. The
collector of the NPN transistor will receive the -0.4 V input.



The LEDs are shrink-wrapped facing one another and further insulated
from light by wrapping in electrical tape. This is important as stray light
can introduce noise.
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Figure 3.2. Novel LED circuit setup. (A) Simple circuitry scheme of LED
circuit. (B) Photographic representation of connections. LED lights are
masked in electrical tape (top) and revealed (bottom).

3.4 Operation Instructions
The novel LED circuit scheme is shown in Figure 3.2A, with an external supply
providing the -0.4V to drive the two LEDs to power a NPN BJT transistor,
enabling the -0.4V to be applied to the carbon-fiber microelectrode (CFM)
through an alligator clip. Alternating from the applied waveform to a constant
potential is under the control of a TTL via a BNC cable. Alternatively, for older
FSCV existing systems, the -0.4V can come from 6052 or 6052e National
Instruments cards. The -0.4V power supply, when coming from the NI boards,
originates from the second analog output (ao1). The first analog output (ao0) is
utilized for the triangle wave output. A DC task for the -0.4V output can be
created in National Instruments Automation Explorer. We do not foresee any
potential safety hazards while setting up or utilizing our described circuit.
Through the use of FSCV software (WCCV or Demon Voltammetry, for
example), FSCAV can be employed using the stimulation settings. The pre-event
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time is set at 2s, the event time at 10s, and the entire file length at 30s. During
the 10s event time, the LED circuit will act as a voltage clamp that will hold the
working electrode at a constant potential of -0.4V (or the resting potential of the
analyte of interest), allowing the analyte to adsorb onto the carbon fiber electrode
and reach equilibrium with its surroundings (Atcherley et al., 2015; Abdalla et al.,
2017). After file collection, analysis can be done by looking at the firstbackground subtracted dopamine cyclic voltammogram (CV) with in-house
LabVIEW 2012 software. It is important to note that the first-background
subtracted dopamine CV becomes visible on the 2 nd or 3rd scan after the
waveform is applied after the constant potential of 10s. Due to electrode
variability, integration limits are set intuitively (Abdalla et al., 2017; Burrell et al.,
2015; Pathirathna et al., 2016).

3.5 Validation and Characterization
In Vitro FSCAV
To test agreement between FSCAV signals obtained with the switch and the LED
circuit, a calibration was performed in vitro (n=6 electrodes). Standard solutions
of dopamine concentrations were prepared by dissolving dopamine hydrochloride
(Sigma-Aldrich, CO., MO, USA) in Tris-buffer (15 mM H2NC-(CH2)(OH)3·HCl, 140
mM NaCl, 3.25 mM KCl, 1.2 mM CaCl2, 1.25 mM NaH2PO4·H2O, 1.2 mM MgCl2,
and 2.0 mM Na2SO4 at pH = 7.4 in deionized water). A calibration was performed
using 50, 100, 200, and 500 nM dopamine concentrations using the dopamine
FSCAV wavefrom (-0.4 V to 1.3 V at 1200 V s-1). These concentrations were
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previously established to be within the linear calibration range for dopamine
FSCAV (Atcherley et al. 2015). Either the switch or the LED circuit was first
utilized to complete a full calibration. The electrode was then cycled in Tris Buffer
for 10 minutes before the same calibration was performed using the other
component. The initiating component was altered between separate electrodes
to reduce biases.
In Figure 3.3A, representative FSCAV color plots obtained with the LED
circuit and switch are shown. The color plots contain the voltage (vs. Ag/AgCl) on
the y-axis, time (30s) on the x-axis, and current (nA) is shown in false color. The
three steps of FSCAV can be seen. Step 1: the waveform is applied to the
carbon-fiber microelectrode at high frequency (100 Hz) to minimize adsorption for
2 seconds (yellow beginning). Step 2: a constant potential being applied for 10
seconds to allow the neurotransmitter to adsorb, reaching a coverage density in
equilibrium with the surroundings (black area). Step 3: the waveform is reapplied
and the adsorbed neurotransmitter is measured in respect to the first step (blue
event area, noted by the starred, dashed white line).
To compare measurements, the 3rd scan was utilized in each system
when a clear, Faradaic dopamine peak was visible. Figure 3.3B shows the
respective current trace of the 3rd scan for the LED circuit (orange) and switch
(blue) with current on the y-axis and time in milliseconds on the x-axis. The
dashed lines note integration limits, or where the area under the curve was
calculated, for the quantification of dopamine for each system. Figure 3.3C is the
resulting calibration plot of the LED circuit and switch with charge (pC) on the y-
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axis and concentration (nM) on the x-axis. Both systems show good agreement
in their measurements with no statistical difference from 50 to 500 nM of
dopamine (n=6; p > 0.05 for all concentrations), consistent with expected in vivo
concentrations (Atcherley et al. 2013).

Figure 3.3. LED Circuit vs. Switch in vitro measurement comparison. (A)
Representative color plots of the LED circuit (top) and switch (bottom) in vitro. (B)
Extracted cyclic voltammograms for the LED circuit (orange) and switch (blue)
from dashed, starred line in A. (C) Calibration plot comparison of the LED circuit
and switch, showing good agreement in their measurements (n=6) + SEM.
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In Vivo FSCAV
After validating that the switch and the LED circuit enable statistically identical
FSCAV measurements in vitro, we moved to comparisons of in vivo responses.
In vivo dopamine measurements were performed in the nucleus accumbens core
(NAcc), a brain locality rich in dopamine terminals (Nirenberg et al., 1997;
Meredith et al., 1992). First, to verify that the electrode was correctly placed in
the NAcc, stimulation of the medial forebrain bundle (MFB) was used to confirm
the release of dopamine with FSCV using a triangular waveform (-0.4V to 1.3V at
400 V s-1). Handling and surgery of 3 male C57BL/6J mice weighing 20-25 g
(Jackson Laboratory, Bar Harbor, ME) were in agreement with The Guide for the
Care and Use of Laboratory Animals and approved by the Institutional Animal
Care Use Committee. Urethane (25% dissolved in 0.9% NaCl solution, Hospira,
Lake Forest, IL) was administered via intraperitoneal (i.p.) injection and
stereotaxic surgery (David Kopf Instruments, Tujunga, CA) was performed. A
heating pad sustained mouse body temperature around 37°C (Braintree
Scientific, Braintree, MA). Stereotaxic coordinates were taken in reference to
bregma. A Nafion modified CFM was inserted into the nucleus accumbens core
(NAcc) (AP: +1.09, ML: -1.25, DV: -4.30). 120 Biphasic pulses were applied
through a linear constant current stimulus isolator (NL800A, Neurolog, Medical
Systems Corp., Great Neck, NY). An Ag/AgCl reference electrode was implanted
into the brain’s opposite hemisphere.
Figure 3.4A (top left) displays the experimental scheme, noting the
working electrode in the NAcc and the stimulating electrode in the MFB. Figure
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3.4B shows the in vivo FSCV color plot, in which the green event denotes the
release of dopamine by stimulation (grey bar below – 2 second duration).
Dopamine is confirmed by its distinctive cyclic voltammogram; oxidation at 0.6 V
and reduction at -0.2 V (white inset taken from the vertical, dashed white line).
Next, the dopamine FSCAV waveform was applied to the working
electrode and the two FSCAV components compared. The components used to
obtain initial in vivo measurements were altered between animals. Figure 3.4C
shows the LED circuit in vivo color plot and corresponding current trace for the
3rd scan, shown by the star and dashed, white line. The integration limits are set
by first placing the final limit where a stable minimum can be found after the
oxidative peak, and then lining up the cross hairs of the initial limit to the final
(Figure 3.4C). It is important to note that the 2nd scan could not be taken for the
LED circuit, as the background, governed by capacitative current, was large
enough (~600 nA) to mask the Faradaic peaks, because of the presence of
additional adsorbing analytes in vivo or more likely stray capacitance from the
BJT transistor. In Figure 3.4D, a color plot and current trace are shown for the
original switch. For the switch’s integration limits, we utilize the 2 nd scan, as
previously published (Atcherley et al., 2015), instead of the 3rd scan, which is
shown by the star and white dashed line. While this scan has a large, nonFaradaic background peak (~350 nA), most importantly, the 2 nd scan has the first
clearly distinguishable Faradaic dopamine peak.
The original work on FSCAV with the switch performed convolution prior to
analysis (Atcherley et al., 2013; Atcherley et al., 2014), however, it has since
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been shown that convolution is not always required (Abdalla et al. 2017; Burrell
et al. 2015; Pathirathna et al., 2016). We did not employ convolution data
analysis to our results. The switch’s integration limits are set by placing both
initial and final limits at the local minima, and encompassing the entire peak. It is
important to note that the integration limits in vivo were altered from the previous
in vitro comparison of both systems to account for the complex matrix of the brain
and additional analytes that are present (Takmakov et al., 2010b; Cahill et al.,
1996; Heien et al., 2004). A post-calibration was performed on the experimental
electrodes using 50, 100, 200, and 500 nM dopamine concentrations.
Using the same calibration concentrations and procedure as the in vitro
experiment, the resulting in vivo dopamine concentration for the switch = 95.0 +
11.0 nM and the novel LED circuit = 94.4 + 7.0 nM. These values are statistically
identical and in good agreement with values that we previously published
(Atcherley et al., 2015) (n=3; p = 0.96).
As a final characterization, the root-mean-square of the signal and noise in
the in vivo recordings was calculated. For a direct comparison, using the 3 rd scan
for both the LED circuit and switch, we found a signal to noise ratio (S/N) of
281.7 and 199.5, respectively. Furthermore, to compare the scans we used for
the in vivo analysis above, we performed the same RMS calculation for the 3 rd
scan of the LED circuit vs. the 2nd scan for the switch. The resulting S/N was
281.7 for the LED circuit and 562.6 for the switch. It is important to note that
during the 2nd scan for the switch, there is a large background peak which
contributes to the signal, as shown in the IT curve in Figure 3.4D. However, as
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previously mentioned, since the first, clear dopamine peak is also obtained
during the 2nd scan, it is feasible to obtain in vivo concentrations of dopamine.
The BJT transistor, utilized by the LED circuit, takes longer to not only shut off,
but may add stray capacitance that appears as additional background in scan 2.
The CMOS precision switch has a much faster switching capability, enabling the
dopamine peak to already appear by the 2nd scan. Nonetheless, it is necessary to
point out that the direct comparison of the 3 rd scan shows a higher S/N for the
LED circuit, indicating it has more favorable recording capabilities in vitro.
Additionally, the LED circuit provides high enough S/N for in vivo measures with
accurate results.
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Figure 3.4. LED Circuit vs. Switch in vivo measurement comparison. (A)
Experimental scheme of in vivo experiments in the mouse brain. (B) FSCV
verification recording of dopamine release in the nucleus accumbens core after
electrical stimulation of the medial forebrain bundle. (C) LED circuit color plot and
extracted cyclic voltammogram from the dashed, starred line (3rd scan). (D)
Switch color plot and extracted cyclic voltammogram from the dashed, starred
line (2nd scan). Integration limits are shown in black, dashed lines.
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Table 3.1 LED Circuit Hardware Specifications
LED Circuit
 Chemistry and Biochemistry
 Neuroscience
 Biological Sciences (e.g. Microbiology
Biochemistry)
Hardware type
 Field measurements and sensors
 Voltammetry
Open Source License Creative Commons Attribution-ShareAlike 3.0
Cost of Hardware
~$5.00
Source File Repository N/A – design included in body of manuscript
Hardware name
Subject area
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and

Table 3.2 LED Circuit Bill of Materials
Designator

Component

#

LED

OP295A
Infrared 890nm LED
BC548CTA
NPN 30V 100mA
565-6741
BNC female

NPN Bipolar
Transistor
BNC
connector

2

Cost per unit
-currency
$0.75

Total cost currency
$1.50

1

$0.20

$0.20

1

$3.49

$3.49
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Source of
materials
Mouser
Electronics
Mouser
Electronics
Mouser
Electronics

Material
type
N/A
N/A
N/A

CHAPTER 4
CONCLUSIONS AND PROSPECTS
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Serotonin is an important biomolecule and key regulator in many neurochemical
pathways. However, a precise definition of normal and irregular serotonin
neurotransmission has yet to be determined due to the lack of tools that can
detect serotonin on a relevant timescale in vivo. This thesis has described the
most recent work done to characterize serotonin’s synaptic activity and elucidate
this transmitter’s distinct function using novel electrochemical techniques.
This thesis addressed the historical challenges of selectively targeting and
measuring serotonin and highlighted FSCV as a powerful electroanalytical
technique that able to overcome these obstacles in order to better understand
phasic-release serotonin dynamics. Furthermore, FSCAV technology has
allowed

for

the

first

rapid

measurement

of

ambient

neurotransmitter

concentrations (Chapter 2). In Chapter 3, simplified instrumentation for fastvoltammetric analysis was developed and characterized to allow non-experts in
electronics and electrochemistry to utilize FSCAV.
To better understand in vivo serotonin dynamics, an innovative platform is
needed to measure serotonin dynamics during real-time environmental stimuli
and behavior. FSCV measurement of serotonin in freely-moving animals would
provide critical information on:
a.

the underlying processes that serotonin encodes

b.

which environmental stimuli induce serotonin release

c.

how serotonin events are time-locked to behavioral events on a
physiologically relevant time scale (10 Hz)

d.

regional differences in the brain for a) - c)
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These topics are routinely studied via dopamine FSCV (Klanker, Feenstra,
Willuhn, & Denys, 2017; Howe, Tierney, Sandberg, Phillips, & Graybiel, 2013).
Therefore, given the development of suitable tools, it is feasible to address these
questions for serotonin as well. It is foreseeable that the concentrations of
evoked serotonin would differ in freely moving vs. anesthetized animals due to
serotonin’s role in circadian rhythms and heightened activity during wakefulness
(Penalva et al., 2003). As a result, even though evoked serotonin levels in
anesthetized animals are low, it is expected that these concentrations may be
higher in freely moving animals.
Currently, all serotonin FSCV experiments utilize acute, glass electrodes
which are lowered the day of electrochemical recording. Due to damage and
stress of implanting the electrode for the animal, it is not recommended to do this
procedure more than once in an individual animal. Thus, chronically implanted
electrodes for serotonin would greatly aide behavior studies so that serotonin
measurements could be conducted for longer periods of time during the evolution
of behavior such as addiction, depression or compulsivity (Clark et al., 2010;
Rodeberg, Sandberg, Johnson, Phillips, & Wightman, 2017).
It will also be of critical importance to record tonic extracellular serotonin in
different disease states, such as depression, to explore whether or not ambient
serotonin levels influence the development, maintenance, or reversal of
neuropsychiatric disorders. The LED circuit was constructed for novices in
electronics and electrochemistry, thus skilled neuroscientists can now utilize this
new technology to measure ambient serotonin in any respective animal model.
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Furthermore, with respect to the rise of novel genetics-based tools for specific
manipulation (i.e. optogenetics and chemogenetics) and execution in mice,
FSCV would act as a neurochemical readout to verify the selectivity of the
manipulation. The coupling of genetic manipulation and serotonin FSCV would
also greatly improve our knowledge of serotonin activity and influences on
behavior, mood, and other neuronal systems. Although these methods are
beginning to be executed in mice, it is crucial to obtain a neurochemical readout
via FSCV to verify the selectivity of the manipulation. Overall, there are still many
questions about serotonergic mechanisms governing healthy brain function that
remain unanswered. Exciting new developments in fast-voltammetric techniques
mean that the scientific community is one step closer to unraveling the function of
this elusive neurotransmitter.

56

REFERENCES
Abdalla, A. et al. (2017). In Vivo Ambient Serotonin Measurements at CarbonFiber Microelectrodes. Analytical Chemistry, 89(18), pp. 9703-9711.
Anastasio, et al. (2013). Functional Status of the Serotonin 5-HT2C Receptor (5HT2CR) Drives Interlocked Phenotypes that Precipitate Relapse-Like
Behaviors in Cocaine Dependence. Neuropsychopharmacology, 39(2), pp.
370-382.
Atcherley, C.W., Laude, N.D., Parent, K.L., & Heien, M.L. (2013). Fast-scan
controlled-adsorption voltammetry for the quantification of absolute
concentrations and adsorption dynamics. Langmuir, 29(48), pp. 1488514892.
Atcherley, C.W., Laude, N.D., Monroe, E.B., Wood, K.M., Hashemi, P., & Heien,
M.L. (2014). Improved Calibration of Voltammetric Sensors for Studying
Pharmacological Effects on Dopamine Transporter Kinetics in Vivo. ACS
Chemical Neuroscience, 6, pp. 1509-1516.
Atcherley, C.W., Wood, K.M., Parent, K.L., Hashemi, P., & Heien, M.L. (2015).
The coaction of tonic and phasic dopamine dynamics. Chemical
Communications, 51(12), pp. 2235-2238.
Baganz, N.L., et al. (2008). Organic cation transporter 3: Keeping the brake on
extracellular serotonin in serotonin-transporter-deficient mice. Proceedings
of the National Academy of Sciences, 105(48), pp. 18976-18981.
Baganz, N.L. & Blakely, R.D. (2012). A Dialogue between the Immune System
and Brain, Spoken in the Language of Serotonin. ACS Publications, 4(1),
pp. 48–63.
Barnes, N.M. & Sharp, T. (1999). A review of central 5-HT receptors and their
function. Neuropharmacology, 38, pp. 1083-1152.
Borland, L.M., Shi, G., Yang, H., & Michael, A.C. (2005). Voltammetric study of
extracellular dopamine near microdialysis probes acutely implanted in the
striatum of the anesthetized rat. Journal of neuroscience methods, 146(2),
pp. 149-158.
Brazell, M.P., Kasser, R.J., Renner, K.J., Feng, J., Moghaddam, B., & Adams,
R.N. (1987). Electrocoating carbon fiber microelectrodes with Nafion

57

improves selectivity for electroactive neurotransmitters. Journal of
neuroscience methods, 22(2), pp. 167-172.
Brown, R.E., Stevens, D.R. & Haas, H.L. (2001). The physiology of brain
histamine. Progress in Neurobiology, 63(6), pp. 637–672.
Bunin, M.A., Prioleau, C., Mailman, R.B., & Wightman, R.M. (1998). Release and
uptake rates of 5-hydroxytryptamine in the dorsal raphe and substantia
nigra reticulate of the rat brain. Journal of neurochemistry, 70(3), pp.
1077-1087.
Bunin, M.A. & Wightman R.M. (1998). Quantitative evaluation of 5hydroxytryptamine (serotonin) neuronal release and uptake: an
investigation of extrasynaptic transmission. Journal of Neuroscience, 18,
pp. 4854-4860.
Burmeister, J.J., Lungren, E.M., Kirschner, K.F., & Neisewander, J.L. (2004).
Differential roles of 5-HT receptor subtypes in cue and cocaine
reinstatement of cocaine-seeking behavior in rats.
Neuropsychopharmacology, 29(4), pp. 660.
Burrell, M.H., Atcherley, C.W., Heien, M.L., & Lipski, J. (2015). A novel
electrochemical approach for prolonged measurement of absolute levels
of extracellular dopamine in brain slices. ACS chemical neuroscience,
6(11), pp. 1802-1812.
Cahill, P.S., Walker, Q.D., Finnegan, J.M., Mickelson, G.E., Travis, E.R., &
Wightman, R.M. (1996). Microelectrodes for the measurement of
catecholamines in biological systems. Analytical Chemistry, 68(18), pp.
3180-3186.
Calizo, L.H., et al. (2011). Raphe serotonin neurons are not homogenous:
electrophysiological, morphological, and neurochemical evidence.
Neuropharmacology, 61(3), pp. 524-543.
Cammack, J., Ghasemzadeh, B., & Adams, R.N. (1991). The pharmacological
profile of glutamate-evoked ascorbic acid efflux measured by in vivo
electrochemistry. Brain Research, 565, pp. 17-22.
Celada, P., Puig, M.V., Casanovas, J.M., Guillazo, G., & Artigas, F. (2001).
Control of Dorsal Raphe Serotonergic Neurons by the Medial Prefrontal
Cortex: Involvement of Serotonin-1A, GABA, and Glutamate Receptors.
Journal of Neuroscience, 21(24), pp. 9917–9929.
Challis, C., et al. (2013). Raphe GABAergic neurons mediate the acquisition of
avoidance after social defeat. Journal of Neuroscience, 33(35), pp. 1397813988.

58

Charara, A. & Parent, A. (1998). Chemoarchitecture of the primate dorsal raphe
nucleus. Journal of chemical neuroanatomy, 15(2), pp. 111-127.
Chase, T.N. & Murphy, D.L. (1973). Serotonin and Central Nervous System
Function. Annual Review of Pharmacology, 13(1), pp.181–197.
Cheer, J.F., Aragona, B.J., Heien, M.L., Seipel, A.T., Carelli, R.M., & Wightman,
R.M. (2007). Coordinated accumbal dopamine release and neural activity
drive goal-directed behavior. Neuron, 54(2), pp. 237-244.
Chefer V.I., Thompson, A.C., Zapata, A., & Shippenberg, T.S. (2009). Overview
of brain microdialysis. Current protocols in neuroscience, 47(1), pp. 7-11.
Clark, J.J., et al., (2010). Chronic microsensors for longitudinal, subsecond
dopamine detection in behaving animals. Nature methods, 7(2), pp. 126.
Correia, P.A., Lottem, E., Banerjee, D., Machado, A.S., Carey, M.R., & Mainen,
Z.F. (2017). Transient inhibition and long-term facilitation of locomotion by
phasic optogenetic activation of serotonin neurons. eLife, 6.
Daws, L.C., Toney, G.M., Davis, D.J., Gerhardt, G.A., & Frazer, A. (1997). In vivo
chronoamperometric measurements of the clearance of exogenously
applied serotonin in the rat dentate gyrus. Journal of neuroscience
methods, 78(1-2), pp. 139-150.
Daws, L.C., Toney, G.M., Gerhardt, G.A., & Frazer, A. (1998). In vivo
chronoamperometric measures of extracellular serotonin clearance in rat
dorsal hippocampus: contribution of serotonin and norepinephrine
transporters. The Journal of pharmacology and experimental therapeutics,
286(2), pp. 967–976.
Daws, L.C., et al. (2005). Transport mechanisms governing serotonin clearance
in vivo revealed by high-speed chronoamperometry. Journal of
neuroscience methods, 143(1), pp. 49-62.
Daws, L.C. & Toney G.M. (2007). High-speed chronoamperometry to study
kinetics and mechanisms for serotonin clearance in vivo. In Hua, Y. &
Michael, A.C. (Eds), Electrochemical Methods for Neuroscience. Boca
Raton (FL): CRC Press/Taylor & Francis.
Daws, L.C., Koek, W., & Mitchell, N.C. (2013). Revisiting Serotonin Reuptake
Inhibitors and the Therapeutic Potential of “Uptake-2” in Psychiatric
Disorders. ACS Chemical Neuroscience, 4(1), pp. 16-21.
Day, J.J., Roitman, M.F., Wightman, R.M., & Carelli, R.M. (2007). Associative
learning mediates dynamic shifts in dopamine signaling in the nucleus
accumbens. Nature neuroscience, 10(8), pp. 1020.

59

DeFelipe, J. & Jones, E.G. (1988). A light and electron microscopic study of
serotonin-immunoreactive fibers and terminals in the monkey sensorymotor cortex, Experimental Brain Research, 71, pp. 171-182.
Ellenroek, B. & Youn, J. (2016). Rodent models in neuroscience research: is it a
rat race? Disease models & mechanisms, 9(10), pp. 1079-1087.
Esbenshade, T.A., Browman, K.E., Bitner, R.S., Strakhova, M., Cowart, M.D., &
Brioni, J.D. (2008). The histamine H3 receptor: an attractive target for the
treatment of cognitive disorders. British Journal of Pharmacology, 154, pp.
1166-1181.
Fink, K., Schlicker, E., Neise, A., & Gothert, M. (1990). Involvement of
presynaptic H3 receptors in the inhibitory effect of histamine on serotonin
release in the rat brain cortex. Naunyn-Schmiedeberg’s archives of
pharmacology, 342(5), pp. 513-519.
Flagel, S.B. et al. (2011). A selective role for dopamine in stimulus-reward
learning. Nature, 469(7328), pp. 53.
France, C.P., Li, J.X., Owens, W.A., Koek, W., Toney, G.M., & Daws, L.C.
(2009). Reduced effectiveness of escitalopram in the forced swimming
test is associated with increased serotonin clearance rate in foodrestricted rats. International Journal of Neuropsychopharmacology, 12(6),
pp. 731-736.
Fronseca, M.S., Murakami, M., & Mainen, Z.F. (2015). Activation of dorsal raphe
serotonergic neurons promotes waiting but is not reinforcing. Current
Biology, 25(3), pp. 306-315.
Fuller, R.W., Perry, K.W, & Molloy, B.B. (1974). Effect of an uptake inhibitor on
serotonin metabolism in rat brain: studies with 3-(ptrifluoromethylphenoxy)-N-methyl-3-phenylpropylamine (Lilly 110140). Life
sciences, 15(6), pp. 1161-1171.
Fuller, R.W. & Wong, D.T. (1977). Inhibition of serotonin reuptake. Federation
proceedings, 36(8), pp. 2154-2158.
Fuller, R.W. (1994). Uptake inhibitors increase extracellular serotonin
concentration measured by brain microdialysis. Life sciences, 55(3), pp.
163-167.
Gelenberg, A.J. & Chesen, C.L. (2000). How fast are antidepressants? Journal of
Clinical Psychiatry, 61, pp. 712-721.
Gerhardt, G.A., Oke, A.F., Nagy, G., Moghaddam, B., & Adams, R.N. (1984).
Nafion-coated electrodes with high selectivity for CNS electrochemistry.
Brain research, 290(2), pp. 390-395.

60

Griessenauer, C.J., et al. (2010). WINCS-based wireless electrochemical
monitoring of serotonin (5-HT) using fast-scan cyclic voltammetry: proof of
principle. Journal of Neurosurgery, 113(3), pp. 656-665.
Haas, H.L., Sergeeva, O.A. & Selbach, O. (2008). Histamine in the Nervous
System. Physiological Reviews, 88(3), pp. 1183–1241.
Hainer, C., et al. (2015). Beyond Gene Inactivation: Evolution of Tools for
Analysis of Serotonergic Circuitry. ACS Chemical Neuroscience, 6(7), pp.
1116-1129.
Hamid, A.A., et al. (2016). Mesolimbic dopamine signals the value of work.
Nature neuroscience, 19(1), pp. 117.
Hashemi, P., Dankoski, E.C., Petrovic, J., Keithley, R.B., & Wightman, R.M.
(2009). Voltammetric detection of 5-hydroxytryptamine release in the rat
brain. Analytical chemistry, 81(22), pp. 9462–9471.
Hashemi, P., Dankoski, E.C., Wood, K.M., Ambrose, R.E., & Wightman, R.M.
(2011). In vivo electrochemical evidence for simultaneous 5‐HT and
histamine release in the rat substantia nigra pars reticulata following
medial forebrain bundle stimulation. Journal of Neurochemistry, 118(5),
pp. 749–759.
Hashemi, P., Dankoski, E.C., Lama, R., Wood, K.M., Takmakov, P., & Wightman,
M.R. (2012). Brain dopamine and serotonin differ in regulation and its
consequences. Proceedings of the National Academy of Science of the
USA, 109(29), pp. 11510-11515.
Heien, M.L., Phillips, P.E., Stuber, G.D., Seipel, A.T., & Wightman, R.M. (2003).
Overoxidation of carbon-fiber microelectrodes enhances dopamine
adsorption and increase sensitivity. Analyst, 128(12), pp. 1413-1419.
Heien, M.L., Johnson, M.A., & Wightman, R.M. (2004). Resolving
neurotransmitters detected by fast-scan cyclic voltammetry. Analytical
Chemistry, 76(19), pp. 5697-5704.
Hersman, S., Cushman, J., Lemelson, N., Wassum, K., Lotfipour, S., &
Fanselow, M.S. (2017). Optogenetic excitation of cholinergic inputs to
hippocampus primes future contextual fear associations. Scientific
Reports, 7(1), pp. 2333.
Holtzheimer, P.E. & Mayberg, H.S. (2011). Deep brain stimulation for psychiatric
disorders. Annual Review of Neuroscience, 34, pp. 289-307.
Hornung, J.P. (2003). The human raphe nuclei and the serotonergic system.
Journal of Chemical Neuroanatomy, 26(4), pp. 331–343.

61

Howe, M.W., Tierney, P.L., Sandberg, S.G., Phillips, P.E., & Graybiel, A.M.
(2013). Prolonged dopamine signaling in striatum signals proximity and
value of distant rewards. Nature, 500(7464), pp. 575.
Howell, J.O., Kuhr, W.G., Ensman, R.E., & Wightman, R.M. (1986). Background
subtraction for rapid scan voltammetry. Journal of Electroanalytical
Chemistry, 209, pp. 77-90.
Jackson, B.P., Dietz, S.M., & Wightman, R.M. (1995). Fast-scan cyclic
voltammetry of 5-hydroxytryptamine. Analytical Chemistry, 67(6), pp.
1115-1120.
Jain, N., Qi., H.X., Collins, C.E., & Kaas, J.H. (2008). Large-scale reorganization
in the somatosensory cortex and thalamus after sensory loss in macaque
monkeys. Journal of Neuroscience, 28(43), pp. 11042-11060.
Jin, Y. et al., (2016). Regrowth of serotonin axons in the adult mouse brain
following injury. Neuron, 91(4), pp. 748-762.
Jaquins-Gerstl, A. & Michael, A.C. (2015). A review of the effects of FSCV and
microdialysis measurements on dopamine release in the surrounding
tissue. Analyst, 70(2), pp. 584-593.
Jennings, K.A. (2013). A comparison of the subsecond dynamics of
neurotransmission of dopamine and serotonin. ACS Chemical
Neuroscience, 4, pp. 704-714.
Kirby, L.G., Rice, K.C., & Valentina, R.J. (2000). Effects of CorticotropinReleasing Factor on Neuronal Activity in the Serotonergic Dorsal Raphe
Nucleus. Neuropsychopharmacology, 22(2), pp. 148-162.
Klanker, M., Feenstra, M., Willuhn, I., and Denys, D. (2017). Deep brain
stimulation of the medial forebrain bundle elevates striatal dopamine
concentration without affecting spontaneous or reward-induced phasic
release. Neuroscience, 19(364), pp. 82-92.
Klingauf, J., Kavalali, E.T. & Tsien, R.W. (1998). Kinetics and regulation of fast
endocytosis at hippocampal synapses. Nature, 394(6693), pp. 581–585.
Lee, W.H. et al. (2016). Microfabrication and in vivo performance of a
microdialysis probe with embedded membrane. Analytical chemistry,
88(2), pp. 1230-1237.
Liu, Y. et al. (2010). Capillary ultrahigh performance liquid chromatography with
elevated temperature for sub-one minute separations of basal serotonin in
submicroliter brain microdialysate samples. Analytical chemistry, 82(23),
pp. 9611-9616.

62

Liu, Z. et al. (2014). Dorsal Raphe Neurons Signal Rewards through 5-HT and
Glutamate. Neuron, 81(6), pp. 1360-1374.
Mathews, T.A., Fedele, D.E., Coppelli, F.M., Avila, A.M., Murphy, D.L., &
Andrews, A.M. (2004). Gene dose-dependent alterations in extraneuronal
serotonin but not dopamine in mice with reduced serotonin transporter
expression. Journal of neuroscience methods, 140(1-2), pp. 169-181.
McElligot, Z. (2015). Optogenetic and Chemogenetic Approaches to Advance
Monitoring Molecules. ACS Chemical Neuroscience, 6, pp. 944-947.
McIlwain, H.J., Thomas, J., & Bell, J.L. (1956). The composition of isolated
cerebral tissues: ascorbic acid and cozymase. Biochemical Journal, 64(2),
pp. 332.
Meredith, G.E, Agolia, R., Arts, M.P.M., Groenewegen, H.J., & Zahm, D.S.
(1992). Morphological differences between projection neurons of the core
and shell in the nucleus-accumbens of the rat. Neuroscience 50(1), pp.
149-162.
Miller, E.K., & Cohen, J.D. (2001). An integrative theory of prefrontal cortex
function. Annual review of neuroscience, 24(4), pp. 167-202.
Mitchell, E.C., Dunaway, L.E., McCarty, G.S., & Sombers, L.A. (2017).
Spectrochemical Characterization of the Dynamic Carbon-Fiber Surface in
Response to Electrochemical Conditioning. Langmuir, 33(32), pp. 78387846.
Miyazaki, K.W., Miyazaki, K., & Doya, K. (2011). Activation of the central
serotonergic system in response to delayed but not omitted rewards.
European Journal of Neuroscience, 33(1), pp. 153-160.
Miyazaki, K., Miyazaki, K.W., & Doya, K. (2012). The role of serotonin in the
regulation of patience and impulsivity. Molecular Neurobiology, 45(2), pp.
213-224.
Miyazaki, K.W., Miyazaki, K., & Doya, K. (2012). Activation of dorsal raphe
serotonin neurons is necessary for waiting for delayed rewards. Journal of
Neuroscience, 32(31), pp. 10451-10457.
Miyazaki, K.W., et al. (2014). Optogenetic activation of dorsal raphe serotonin
neurons enhances patience for future rewards. Current Biology, 24(17),
pp. 2023-2040.
Monachon, M.A., Burkhard, W.P., Jalfre, M., & Haefely, W. (1972). Blockade of
central 5-hydroxytryptamine receptors by methiothepin. NaunynSchmiedeberg’s Archives of Pharmacology, 274, pp. 192-197.

63

Montañez, S., Munn, J.L., Owens, W.A., Horton, R.E., & Daws, L.C. (2014). 5HT1B receptor modulation of the serotonin transporter in vivo: studies
using KO mice. Neurochemistry international, 73, pp. 127–131.
Moran, R.J. et al., (2018). The protective action encoding of serotonin transients
in the human brain. Neuropsychopharmacology, pp. 1-11.
Muller, C.P. & Jacobs, B. (2009). Handbook of the behavioral neurobiology of
serotonin, 21. Academic Press.
Murphy, D.L. et al. (2003). Experimental gene interaction studies with SERT
mutant mice as models for human polygenic and epistatic traits and
disorders. Genes, Brain and Behavior, 2(6), pp. 350–364.
Nagy, G. et al. (1985). Ion exchange and transport of neurotransmitters in nation
films on conventional and microelectrode surfaces. Journal of
electroanalytical chemistry and interfacial electrochemistry, 188(1-2), pp.
85-94.
Nandi, P. & Lunte, S.M. (2009). Recent trends in microdialysis sampling
integrated with conventional and microanalytical systems for monitoring
biological events: a review. Analytica chimica acta, 651(1), pp. 1-14.
Nautiyal, K.M. & Hen, R. (2017). Serotonin receptors in depression: from A to B.
F1000Research, 6.
Nieuwenhuys, R., Geeraedts, L.M., & Veening, J.G. (1982). The medial forebrain
bundle of the rat. I. General introduction. The Journal of Comparative
Neurology, 206, pp. 48-81.
Nirenberg, M., et al. (1997). The dopamine transporter: Comparative
ultrastructure of dopaminergic axons in limbic and motor compartments of
the nucleus accumbens. Journal of Neuroscience 17(18), pp. 6899-6907.
Oldham, K. (1986). Convolution of voltammograms as a method of chemical
analysis. Journal of the Chemical Society, Faraday Transactions, 82, pp.
1099-1104.
Palkovits, M., Brownstein, M., & Saavedra, J.M. (1974). Serotonin content of the
brain stem nuclei in the rat. Brain research, 80(2), pp. 237-249.
Pathirathna, P., Siriwardhane, T., McElmurry, S.P., Morgan, S.L., & Hashemi, P.
(2016). Fast voltammetry of metals at carbon-fiber microelectrodes:
towards an online speciation sensor. Analyst, 141, pp. 6432-6437.
Paxinos, G. & Watson, C. (2007). The Rat Brain in Stereotaxic Coordinates.
London: Academic Press.

64

Penalva, R.G., Lancel, M., Flachskamm, C., Reul, J.M., Holsboer, F., Linthorst,
A.C. (2003). Effect of sleep and sleep deprivation on serotonergic
neurotransmission in the hippocampus: a combined in vivo
microdialysis/EEG study in rats. European Journal of Neuroscience, 17(9),
pp. 1896-1906.
Phillips, P.E.M., Robinson, D.L., Stuber, G.D., Carelli, R.M., & Wightman, R.M.
(2003). Real-time measurements of phasic changes in extracellular
dopamine concentration in freely moving rats by fast-scan cyclic
voltammetry. In Drugs of Abuse (pp. 443-464). Humana Press.
Phillips, P.E.M. & Wightman, M.R. (2003). Critical guidelines for validation of the
selectivity of in-vivo chemical microsensors. Trends in Analytical
Chemistry, 22(9), pp. 509-514.
Qi, J., et al. (2014). A glutamatergic reward input from the dorsal raphe to ventral
tegmental area dopamine neurons. Nature communication, 12(5), pp.
5390.
Reubi, J.C. & Emson, P.C. (1978). Release and distribution of endogenous 5-HT
in rat substantia nigra. Brain research, 139(1), pp. 164-168.
Rice, M.E. & Nicholson, C. (1989). Measurement of nanomolar dopamine
diffusion using low-noise perfluorinated ionomer coated carbon fiber
microelectrodes and high-speed cyclic voltammetry. Analytical Chemistry,
61(17), pp. 1805-1810.
Robinson, D.L., Venton, B.J., Heien, M.L., & Wightman, R.M. (2003). Detecting
subsecond dopamine release with fast-scan cyclic voltammetry in vivo.
Clinical Chemistry, 49(10), pp. 1763-1773.
Rodeberg, N.T., Sandberg, S.G., Johnson, J.A., Phillips, P.E., & Wightman, R.M.
(2017). Hitchhiker’s guide to voltammetry: acute and chronic electrodes for
in vivo fast-scan cyclic voltammetry. ACS chemical neuroscience, 8(2), pp.
221-234.
Russell, W.L., Henry, D.P., Phebus, L.A., & Clemens, J.A. (1990). Release of
histamine in rat hypothalamus and corpus striatum in vivo. Brain research,
512(1), pp. 95–101.
Sakowski, S.A., Geddes, T.J., Thomas, D.M., Levi, E., Hatfield, J.S., & Kuhn,
D.M. (2006). Differential tissue distribution of tryptophan hydroxylase
isoforms 1 and 2 as revealed with monospecific antibodies. Brain
Research, 1085(1), pp. 104-114.
Samaranayake, S. et al., (2016). A voltammetric and mathematical analysis of
histaminergic modulation of serotonin in the mouse hypothalamus. Journal
of Neurochemistry, 138(3), pp. 374–383.
65

Sara, Y., Mozhayeva, M.G., Liu, X., & Kavalali, E.T. (2002). Fast Vesicle
Recycling Supports Neurotransmission during Sustained Stimulation at
Hippocampal Synapses. Journal of Neuroscience, 22(5), pp.1608–1617.
Schenk, J.O., Miller, E., Gaddis, R., & Adams, R.N. (1982). Homeostatic control
of ascorbate concentration in CNS extracellular fluid. Brain research,
253(1-2), pp. 353-356.
Schlicker, E., Betz, R., & Gothert, M. (1988). Histamine H3 receptor-mediated
inhibition of serotonin release in the rat brain cortex. Naunyn
Schmiedeberg’s Archives of Pharmacology, 337, pp. 588-590.
Shaskan, E.G. & Snyder, S.H. (1970). Kinetics of serotonin accumulation into
slices from rat brain: relationship to catecholamine uptake. The Journal of
pharmacology and experimental therapeutics, 175, pp. 404-418.
Shen, H.W., et al. (2004). Regional differences in extracellular dopamine and
serotonin assessed by in vivo microdialysis in mice lacking dopamine
and/or serotonin transporters. Neuropsychopharmacology, 29(10), pp.
1790.
Song, R. et al., (2012). Increase vulnerability to cocaine in mice lacking
dopamine D3 receptors. Proceedings of the National Academy of
Sciences of the USA, 109, pp. 17675-17680.
Srejic., L.R. et al., (2014). Paired pulse depression in the subcallosal cingulate
region of depression patients. Biological Psychiatry, 78(1), pp. e3-e4.
Srejic, L.R., Wood, K.M., Zeqja, A., Hashemi, P., & Hutchinson, W.D. (2016).
Modulation of serotonin dynamics in the dorsal raphe nucleus via high
frequency medial prefrontal cortex stimulation. Neurobiology of disease,
94, pp.129–138.
Stamford, J.A., Kruk, Z.L., Millar, J. (1990). Striatal dopamine terminals release
serotonin after 5-HTP pretreatment: in vivo voltammetric data. Brain
research, 515(1-2), pp. 173-180.
Strand, A.M. & Venton, B.J. (2008). Flame etching enhances the sensitivity of
carbon-fiber microelectrodes. Analytical chemistry, 80(10), pp. 3708-3715.
Takmakov, P. et al. (2010). Carbon microelectrodes with a renewable surface.
Analytical chemistry, 82(5), pp. 2020-2028.
Takmakov, P., Zachek, M.K., Keithley, R.B., Bucher, E.S., McCarty, G.S., &
Wightman, R.M. (2010b). Characterization of Local pH Changes in Brain
Using Fast-Scan Cyclic Voltammetry with Carbon Microelectrodes.
Analytical Chemistry, 82(23), pp. 9892-9900.

66

Threlfell, S. et al. (2004). Histamine H3 receptors inhibit serotonin release in
substantia nigra pars reticulate. The Journal of Neuroscience, 24, pp.
8704-8710.
Tye, K.M., et al. (2013). Dopamine neurons modulate neural encoding and
expression of depression-related behavior. Nature, 493(7433), pp. 537.
Volle, J., et al. (2018). Deep brain stimulation and fluoxetine exert different longterm changes in the serotonergic system. Neuropharmacology, 135, pp.
63-72.
Walther, D.J. & Bader, M. (2003). A unique central tryptophan hydroxylase
isoform. Biochemical Pharmacology, 66(9), pp. 1673-1680.
Weissbourd, B., Ren, J., DeLoach, K.E., Guenthner, C.J., Miyamichi, K., & Luo,
L. (2014). Presynaptic partners of dorsal raphe serotonergic and
GABAergic neurons. Neuron, 83(3), pp. 645–662.
West, A.W., Best, J., Abdalla, A., Nijhout, F., Reed, M., Hashemi, P. (2018).
Voltammetric Evidence for Discrete Serotonin Circuits, Linked to Specific
Reuptake Domains, in the Mouse Medial Prefrontal Cortex.
Neurochemistry International.
Wightman, R.M., May, L.J., & Michael, A.C. (1988). Detection of dopamine
dynamics in the brain. Analytical chemistry, 60(13), pp. 769A-793A.
Willuhn, I., Burgeno, L.M., Groblewski, P.A., Phillips, P.E. (2014). Excessive
cocaine use results from decreased phasic dopamine signaling in the
striatum. Nature neuroscience, 17(5), pp. 704.
Wood, K. M. & Hashemi, P. (2013). Fast-Scan Cyclic Voltammetry Analysis of
Dynamic Serotonin Responses to Acute Escitalopram. ACS Chemical
Neuroscience, 4, pp. 715-720.
Wood, K.M., Zeqja, A., Nijhout, H.F., Reed, M.C., Best, J., & Hashemi, P. (2014).
Voltammetric and mathematical evidence for dual transport mediation of
serotonin clearance in vivo. Journal of Neurochemistry, 130(3), pp. 351–
359.
Xiao, N., Privman, E., & Venton, J.B. (2014). Optogenetic Control of Serotonin
and Dopamine Release in Drosophila Larvae. ACS Chemical
Neuroscience, 5, pp. 666-673.
Yang, H., Thompson, A.B., McIntosh, B.J., Altieri, S.C., and Andrews, A.M.
(2013). Physiologically relevant changes in serotonin resolved by fast
microdialysis. ACS Chem Neuroscience, 4(5), pp. 790-798.

67

Zhang, J., Jaquins-Gerstl, A., Nesbitt, K.M., Rutan, S.C., Michael, A.C., & Weber,
S.G. (2013). In vivo monitoring of serotonin in the striatum of freely moving
rats with one minute temporal resolution by online microdialysis-capillary
high-performance liquid chromatography at elevated temperature and
pressure. Analytical chemistry, 85(20), pp. 9889-9897.
Zhu, C.B., Linder, K.M., Owens, A.W., Daws, L.C., Blakely, R.D., & Hewlett, W.A.
(2010). Interleukin-1 Receptor Activation by Systemic Lipopolysaccharide
Induces Behavioral Despair Linked to MAPK Regulation of CNS Serotonin
Transporters. Neuropsychopharmacology, 35(13), pp. 2510–2520.
Zhu, K.Y., et al. (2011). The establishment of a sensitive method in determining
different neurotransmitters simultaneously in rat brains by using liquid
chromatography-electrospray tandem mass spectrometry. Journal of
Chromatography B, 879(11-12), pp. 727-742.
Zill, P., Buttner, A., Eisenmenger, W., Moller, H.J., Ackenheil, M., & Bondy, B.
(2007). Analysis of tryptophan hydroxylase I and II mRNA expression in
the human brain: a post-mortem study. Journal of Psychiatric Research,
41(1-2), pp. 168-173.

68

APPENDIX A
PERMISSION OBTAINED FROM AMERICAN CHEMICAL
SOCIETY TO REPRINT FIGURES IN CHAPTER 2

69

Permission for Figure 2.2:

70

Permission for Figure 2.4:

71

APPENDIX B
PERMISSION OBTANED FROM THE ROYAL SOCIETY OF
CHEMISTRY TO REPRINT FIGURE IN CHAPTER 2

72

Permission for Figure 2.3:

73

